Genentech’s Faricimab for Wet AMD May Greatly Extend Time Between Injections

(Updated May 13, 2020) Genentech has announced positive results from the Phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD). At 52 weeks, faricimab patients dosed either every 16 weeks or every 12 weeks demonstrated sustained vision outcomes comparable to Lucentis (ranibizumab) dosed [Read More]


Possible Cause of Charles Bonnet Syndrome Discovered

Researchers at the University of Queensland have found an association between Charles Bonnet Syndrome (CBS) and abnormally heightened activity in the visual cortex of the brain. The findings were published October 25, 2018 in the journal Current Biology. According to the researchers, up to 40% of people with loss of vision experience hallucinations, which are [Read More]

Primary Care Physicians Are Neglecting Vision

A report from the National Poll on Healthy Aging reveals that more than half of older patients surveyed said their primary care providers have not asked them about their vision. Considering the number of ailments that can affect the aging population, vision is unfortunately often overlooked. This is concerning, since the incidence of age-related macular [Read More]

FTC Stops Deceptive Claims About Stem Cell Therapy

California companies lacked scientific evidence that their “amniotic stem cell therapy” could treat or cure macular degeneration and other serious diseases. A California-based physician and the two companies he controls have settled charges of deceptively advertising that “amniotic stem cell therapy” can treat serious diseases, including Parkinson’s disease, autism, macular degeneration, cerebral palsy, multiple sclerosis, [Read More]

Second Trial Showing Efficacy for Stem Cell Treatment of Dry AMD

A second trial begun in 2018 is showing positive results with replacing defective cells leading to vision loss from dry (geographic) macular degeneration. Implanted cells derived from stem cells have been implanted into five patients by researchers from University of Southern California (USC) and the University of California, Santa Barbara. Results at one year have [Read More]